AmVac, AG: Series A $2.8M

Posted in I - Series A, Q - 4Q09, R - INTERNATIONAL, X - BPH, X - RSV, X - Vaginitis

AmVac (Switzerland) a development-stage vaccine company focused on vaginitis , BPH and RSV, closed a $2.8M Series A financing bringing the total round to $4M. Participants include Venture+ and Co Fonds 2.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Jan

2010

Pulmatrix, Inc.: Series B $30.2M

Posted in I - Series B, Q - 4Q09, R - NORTH EAST, X - Antiinfective, X - Asthma, X - COPD, X - Influenza, X - RSV, X - Respiratory, XX - MA

Pulmatrix (Lexington, MA) a clinical-stage biotechnology company focused on the discovery and development of therapies for the treatment and prevention of infectious (COPD, asthma, and cystic fibrosis) and progressive respiratory (influenza, ventilator acquired pneumonia and respiratory syncytial virus (RSV)) diseases, closed a $30.2M Series B financing. Participants include Arch Venture Partners, Novartis Ventures Funds,Polaris Venture [...]

Jun

2009

VaxInnate Corp., Series D $30M

Posted in I - Series D, Q - 2Q09, R - NORTH EAST, X - Dengue, X - HPV, X - RSV, X - Vaccines, XX - NJ

VaxInnate (Cranbury, NJ) a clinical-stage vaccine company focused on infectious disease including flu, malaria, dengue, papillomavirus, and respiratory syncytial virus, closed a $30M Series D financing. Participants include Wellcome Trust, New Leaf Venture Partners, Canaan Partners, HealthCare Ventures, Oxford Bioscience Partners, MedImmune Ventures and CHL Medical Partners.

to top of page...